Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).

Krishan K. Sharma, Juan Felipe Rico, MD, Michael W. Becker, MD, Gail J. Roboz, MD, Gabriela Chiosis, PhD, Monica L. Guzman, PhD

Blood (2012) 120 (21): 2476.

https://doi.org/10.1182/blood.V120.21.2476.2476

Published: 2012

Journal Articles

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Francis J. Giles, MB, MD, FRCPI, FRCPath, Michael J. Mauro, MD, Frank Hong, MD, PhD, MPH, Christine-Elke Ortmann, Richard C. Woodman, Philipp D. LeCoutre, MD, Giuseppe Saglio, MD

Blood (2011) 118 (21): 2757.

https://doi.org/10.1182/blood.V118.21.2757.2757

Published: 2011

Journal Articles

Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status

Harshabad Singh, MBBS, Lillian Werner, Daniel J DeAngelo, MD, PhD, Philip C. Amrein, MD, Martha Wadleigh, M.D., Karen K Ballen, MD, Edward Fox, Ilene Galinsky, ANP, Donna Neuberg, ScD, Richard M Stone, M.D., Eyal C Attar, MD

Blood (2010) 116 (21): 2689.

https://doi.org/10.1182/blood.V116.21.2689.2689

Published: 2010

Journal Articles

Autologous Bone Marrow-Derived Stem Cell Therapy in Patients with Severe Peripheral Arterial Disorders: A Pilot Study.

Zoltan Boda, MD, Miklos Udvardy, M.D., Katalin Razso, M.D., Mariann Szarvas, Katalin Farkas, M.D., Judit Toth, M.D., Laszlo Jambor, M.D., Pal Soltesz, M.D., Zsolt Olah, M.D., Peter Ilonczai, M.D., Janos Hunyadi, M.D., Tamas Sipos, Krisztina Litauszky, M.D., Janos Kappelmayer, M.D., Zoltan Vereb, M.D., Eva Rajnavolgyi, M.D.

Blood (2007) 110 (11): 2877.

https://doi.org/10.1182/blood.V110.11.2877.2877

Published: 2007

Journal Articles

Proteasome Inhibitor Combination with Cytarabine or Arsenic Trioxide Can Potentiate Apoptosis in AML Cells.

Jane L. Liesveld, MD, Camille N. Abboud, MD, Chaohui Lu, Jeremy Bechelli, Karen Rosell, Gordon Phillips, MD, Jeffrey E. Lancet, MD

Blood (2005) 106 (11): 4464.

https://doi.org/10.1182/blood.V106.11.4464.4464

Published: 2005

NARROW

HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status

Autologous Bone Marrow-Derived Stem Cell Therapy in Patients with Severe Peripheral Arterial Disorders: A Pilot Study.

Proteasome Inhibitor Combination with Cytarabine or Arsenic Trioxide Can Potentiate Apoptosis in AML Cells.

Email alerts

ASH Publications

American Society of Hematology

HSP70 Inhibitor, YK5, Synergizes with Chemotherapeutic Agents and Prevents Chemoresistance in Acute Myelogenous Leukemia (AML).

Retrospective Cohort Analysis of Peripheral Arterial Occlusive Disease (PAOD) Events in Patients (pts) with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

Clinical Outcomes of Acute Promyelocytic Leukemia (APL) Patients According to FLT3 Mutation Status

Autologous Bone Marrow-Derived Stem Cell Therapy in Patients with Severe Peripheral Arterial Disorders: A Pilot Study.

Proteasome Inhibitor Combination with Cytarabine or Arsenic Trioxide Can Potentiate Apoptosis in AML Cells.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only